NOAH Compendium

Printed from NOAH Compendium (https://www.noahcompendium.co.uk). (c) Copyright NOAH Compendium 2024. All Rights Reserved.
Date: Saturday, May 18, 2024 17:51

Description: Virbac 2013
Telephone: 01359 243243
Release 3.55
Virbaxyl 10%
 
Species: Horses and other equidae
Therapeutic indication: Pharmaceuticals: Neurological preparations: Tranquilisers
Active ingredient: Xylazine
Product:Virbaxyl 10%
Product index: Virbaxyl 10%
Withdrawal notes: Not for use in horses intended for human consumption
Incorporating:
Presentation
Virbaxyl 10% is a clear, colourless aqueous solution for injection. Each ml contains 100 mg xylazine base. The product contains 0.18% w/v methyl hydroxybenzoate and 0.02% w/v propyl hydroxybenzoate as antimicrobial preservatives.
Uses
Virbaxyl 10% is a sedative with analgesic and muscle relaxant properties for use in horses only in cases where sedation is required, including:
1Handling fractious animals e.g. for transportation.
2Medical examinations e.g. X-ray examination, removal of bandages, examination of the penis and oral cavity.
3Premedication for minor superficial operations and local or regional anaesthesia.
4Elimination of defaecation when examining and treating the vagina, uterus and hindquarters.
Dosage and administration
Horses
Virbaxyl 10% is given by slow intravenous injection. Dosage depends upon the degree of sedation required and the response of the animal, and is 0.5–1 ml/100 kg bodyweight. Animals do not usually become recumbent with Virbaxyl 10% and light to deep sedation with variable degree of analgesia is obtained. Effects are usually seen within 5 minutes and persist for approximately 20 minutes. Virbaxyl 10% may be employed as a premedication to barbiturate anaesthesia or in combination with regional or local anaesthesia. Nervous or excitable horses may require higher doses. Older horses and those having undergone severe physical exertion before treatment should receive the lowest dose rate.
Contra-indications, warnings, etc
1Not to be used in horses intended for human consumption.
2Do not administer by the intra-carotid route.
3Virbaxyl 10% should not be administered in the last month of pregnancy because of the risk of inducing premature parturition.
4As the safety of xylazine during organogenesis has not been fully demonstrated by current methods it should be used with caution during the 1st month of pregnancy.
5Careful consideration should be given before administering to animals exposed to stress conditions such as extreme heat, cold, high altitude or fatigue.
6Side effects such as brachycardia, cardiac arrhytmia and polyuria may occur.
7Following intravenous administration, a transient rise followed by a fall in blood pressure usually occur.
Operator warnings
8Xylazine is an alpha adrenoceptor agonist acting primarily on alpha-2 receptors.
9Precautions should be taken to avoid accidental injection/self-injection.
10Wash splashes from the skin immediately.
11In the event of accidental injection/self-injection, seek urgent medical advice and show label and other product literature. DO NOT DRIVE as sedation and changes in blood pressure may occur.
12Remove contaminated clothes that are in direct contact with the skin
13In the case of accidental contact of the product with the eyes, rinse with large amounts of fresh water. If symptoms occur, seek the advice of a doctor
14If pregnant women handle the product, special precaution should be observed not to self-inject as uterine contractions and decreased foetal blood pressure may occur after accidental systemic exposure
Advice to doctors
Xylazine is an alpha adrenoceptor agonist whose toxicity may cause clinical effects including sedation, respiratory depression, and coma, bradycardia hypotension and hyperglycaemia. Ventricular arrhythmias have also been reported. Treatment should be supportive with appropriate intensive therapy.
Pharmaceutical precautions
Shelf life of the veterinary medicinal product as packaged for sale: 5 years.
Shelf life after first opening of the immediate packaging: 28 days
Do not store above 25°C.
Following withdrawal of the first dose, use the product within 28 days. Discard unused material
Legal category
Legal category: POM-V
Packaging quantities
Vials of 50 ml.
Further information
Nil.
Marketing Authorisation Number
11188/4001.
Significant changes
GTIN